Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva. Despite promising data and market potential, UroGen's low market cap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback